Dr. Reddy's Laboratories Limited (BVMF:R1DY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 51.58B -17.4% |
| Revenue (ttm) | 18.15B -0.9% |
| Net Income | 1.81B -41.7% |
| EPS | 2.18 -41.7% |
| Shares Out | n/a |
| PE Ratio | 28.43 |
| Forward PE | 23.86 |
| Dividend | 0.06 (0.50%) |
| Ex-Dividend Date | Jul 8, 2026 |
| Volume | 1 |
| Open | 12.10 |
| Previous Close | 12.40 |
| Day's Range | 12.10 - 12.10 |
| 52-Week Range | 10.80 - 13.81 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 22, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as ... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial numbers in INR Financial StatementsNews
DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY). The inv...
Laurus Labs surges past Rs 1 lakh crore MCAP & biggies like Dr Reddy’s
Laurus Labs hits Rs 1 lakh crore market cap as shares rally 115% in a year, overtaking Dr Reddy’s and Aurobindo; Divi’s crosses Rs 2.2 lakh crore.
Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced the U.S. launch of its Sugammadex Injection in single-dose vials of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), marking the first gen...
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, i...
Dr Reddy’s registers PD-1 inhibitor for rare head and neck cancer in South Africa
Dr Reddy’s Labs South Africa registers a PD-1 inhibitor for recurrent/metastatic nasopharyngeal carcinoma, aiming to expand access to oncology care.
Dr Reddy’s gets USFDA nod for Rituximab biosimilar
USFDA approves Dr Reddy’s rituximab biosimilar to Rituxan; Fresenius Kabi to exclusively commercialise in the US, expanding Dr Reddy’s biologics portfolio.
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%. NEW YORK, July 31, 2026 /PRNewswire/ ...
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)
RDY shares fell approximately 9% after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches. The investigation focuses on the Company's regulatory statements about se...
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)
NEW YORK--(BUSINESS WIRE)--RDY shareholders saw Dr. Reddy's Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a ₹2.4 billion provision tied to out-...
Thailand approves Nuzolvence antibiotic for gonorrhoea treatment
Thailand approves Nuzolvence (zoliflodacin), a first-in-class oral gonorrhoea antibiotic, for patients 12+; Dr Reddy’s and GARDP led review amid resistance.
Trump's Tariffs Are Targeting Indian Drugmakers. Americans Could Soon Pay More for Generic Medicines, CEO Warns
Erez Israeli, CEO of Dr. Reddy's Laboratories, said that President Donald Trump's proposed tariffs on imported generic medicines would inevitably translate into higher prices for patients.
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)
RDY shares fell approximately 9% after Q1 FY27 results showed a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investor losses tied to the market reactio...
U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO
In this CNBC exclusive, Dr. Reddy's Laboratories CEO Erez Israeli breaks down the company's recent Q1 earnings report. He addresses the temporary halt in Semaglutide production due to an impurity issu...
U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
U.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing ...
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells Investors
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells Investors
Dr Reddy's Laboratories Ltd Annual Shareholders Meeting Transcript
Dr Reddy's Laboratories Ltd Annual Shareholders Meeting Transcript
Dr. Reddy's Laboratories Q1 Net Profit Drops As Revenue Slips, Expenses Climb
(RTTNews) - Dr. Reddy's Laboratories Limited (RDY, 500124, DRREDDY), a major Indian pharmaceutical company, on Thursday posted a decline in net income for the first quarter, hurt by decreased revenue ...
U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO
In this CNBC exclusive, Dr. Reddy's Laboratories CEO Erez Israeli breaks down the company's recent Q1 earnings report. He addresses the temporary halt in Semaglutide production due to an impurity issu...
Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes
Shares of Dr Reddy's Laboratories declined 4.4% on Thursday after brokerages cut their earnings forecasts for the Indian drugmaker after weaker-than-expected quarterly results and semaglutide s...
A Look at Dr Reddy's Laboratories Ltd (RDY) After 9.4% Decline -- GF Value $14.70 vs Price $11.38
A Look at Dr Reddy's Laboratories Ltd (RDY) After 9.4% Decline -- GF Value $14.70 vs Price $11.38
Dr. Reddy's Laboratories Enters Oversold Territory (RDY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
Dr. Reddy's Laboratories NYSE: RDY reported a year-over-year revenue decline and sharply lower profitability for the first quarter of fiscal 2027, as lower lenalidomide sales and semaglutide API-relat...
Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's
The United States plans significant tariffs on imported generic medicines. These duties will rise to 200% in the coming years. Dr Reddy's Laboratories anticipates higher medicine prices for American c...
Dr. Reddy's Laboratories Transcript: Q1 26/27
Revenue declined 5.6% year-over-year due to lower lenalidomide sales and semaglutide API issues, but base business delivered double-digit growth across geographies. EBITDA margin was 12.5%, with guidance maintained for 20% margins as semaglutide supplies are expected to resume by November. Strong cash position supports ongoing business development and expansion.
Dr. Reddy's Laboratories Quarterly report: Q1 2027
Dr. Reddy's Laboratories has published its Q1 2027 quarterly earnings report on July 22, 2026.